Introduction
============

Bloodstream infection (BSI) is one of the most severe forms of nosocomial infection, especially in immunocompromised cancer patients. *Escherichia coli* (EC) is a common cause of BSI, and production of extended-spectrum β-lactamase (ESBL) is the main mechanism conferring resistance to third-generation cephalosporins, which results in treatment problems, higher morbidity, mortality, and increased health care costs.[@b1-idr-12-359] Previous studies showed that biofilm formation (BF) is associated with resistance of EC toward antimicrobial drugs, and BF markedly increases the incidence of health care-associated infections, especially in catheter-related BSI.[@b2-idr-12-359]--[@b5-idr-12-359] One study indicated that 60.2% of EC strains were multi-drug resistant (MDR, maximum resistance to ampicillin), and 43% of MDR EC had a biofilm-positive phenotype.[@b2-idr-12-359] BF results in serious clinical problems because of its resistance to host defense systems and to conventional antimicrobial therapy, which substantially hinders various treatments. Although many studies reported that BF is closely associated with EC*-*caused urinary tract infections,[@b2-idr-12-359],[@b6-idr-12-359],[@b7-idr-12-359] more recent studies indicated that bacterial BF might act as a direct triggering factor contributing to cancer initiation and progression. For example, in colorectal cancer experimental models, biofilm microbial populations can significantly impair the intestinal epithelial barrier function, alter poly-amine metabolism affecting cellular proliferation, enhance pro-inflammatory/pro-oncogenic responses, and exacerbate intestinal dysbiosis.[@b8-idr-12-359] The invasive and co-aggregation capacity of microbiota may be essential for biofilm-promoted colon tumorigenesis. In addition, some studies attributed BF-related mortality to certain debatable factors, such as drugs with no activity against BF, biofilm heterogeneity, and the presence of comorbidities.[@b7-idr-12-359],[@b9-idr-12-359] However, to our knowledge, there is little information about how BF contributes to EC-caused BSI, especially to extended-spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC)-caused BSI in cancer patients. Therefore, the aim of this study was to investigate the impact of BF-positive, EC-caused BSI on the clinical outcome of hospitalized cancer patients.

Methods
=======

Setting and study design
------------------------

A retrospective study was conducted at the Tianjin Medical University Cancer Institute and Hospital (<http://www.tjmuch.com/>, <http://www.tjmuch.com/zlyjs/>) between January 2013 and September 2017. All hospitalized cancer patients with the first episode of BSI were included in the study. Cancer patients with polymicrobial BSI, under the age of 18, or with non-EC-caused BSI were excluded from the study. Data retrospectively collected included age, sex, associated diseases, sources of BSI, invasive procedures, such as urinary catheterization or tracheostomy during the preceding 3 months, multiple shot antibiotics therapy during the preceding 3 months, the presence of severe sepsis or septic shock, and in-hospital mortality.

Depending on the different requirements, cancer patients included in this study were divided into the following groups: patients with BSI due to an isolate of ESBL-EC and those with non-ESBL-EC-caused BSI. The two groups were compared in order to identify independent risk factors for ESBL-EC infection. Patients who died were further compared with those who survived to determine predictors for mortality. Furthermore, the outcome differences between BF-positive and BF-negative EC-infected patients or ESBL-EC-infected patients were assessed.

Definition
----------

All cases of cancer were confirmed by pathology. The BSI assessment of whether the isolated organisms represent true BSI, rather than contamination, was made based on the clinical or laboratory evidence of infection: fever, hypothermia, evidence of localized infection, inadequate organ perfusion, severe sepsis, and leukocytosis. The definitions of severe sepsis and septic shock were adapted from the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee.[@b10-idr-12-359] The source of BSI was determined according to the definition of nosocomial infections by the Center for Disease Control and Prevention, and the presence of clinical signs with EC isolation from the presumed source.[@b11-idr-12-359] MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Once a species has intrinsic resistance to certain antimicrobial agents, related antimicrobial classes are not counted when calculating the number of classes to which the isolate is resistant.[@b11-idr-12-359] In-hospital mortality was defined as death by any cause within the first 30 days after the onset of BSI during hospitalization.

Microbiological procedures
--------------------------

Blood cultures (8--10 mL blood from a patient) inoculated in BACTEC plus aerobic/F and anaerobic lytic/10 vials, were incubated using the automated blood culture system (BACTEC FX400; Becton Dickinson, NJ, USA) at 35°C for at least 5 days. Positive cultures were determined with gram staining, and then subcultured on both blood agar and MacConkey plates (JinZhangKeji, Tianjin, China) at 35°C for 18--24 hours. Pathogens identification and susceptibility tests were performed on the Vitek 2 Compact automated microbiology system (BioMerieux, Craponne, France) by using GN and GN67 cards. The Clinical and Laboratory Standards Institute criteria were used to define the susceptibility or the resistance to antimicrobial agents.[@b12-idr-12-359]

ESBL screening, confirmatory test, and gene detection
-----------------------------------------------------

Bacterial isolates identified as EC, were stored on glycerol tryptic soy broth in a --20°C freezer. When a fresh seed-stock vial was required, it was removed and used to inoculate a series of working cultures.

The VITEK 2 Compact was used to screen ESBL-EC. The ESBL confirmatory test was performed using cefotaxime (CTX, 30 µg), ceftazidime (30 µg) alone, or in combination with clavulanate (10 µg) on Mueller-Hinton agar.[@b12-idr-12-359] Strains producing ESBL were confirmed by ≥5 mm increments in zone diameter. EC ATCC25922 (the negative control) and *Klebsiella pneumoniae* ATCC 700603 (the positive ESBL producer) (American Type Culture Collection, USA) were used for quality control.

Detection of ESBL genotype-related gene families (*bla*~TEM~, *bla*~SHV~, and *bla*~CTX-M~) was performed using PCR with primers ([Table S1](#SD2-idr-12-359){ref-type="supplementary-material"}) and conditions previously described.[@b13-idr-12-359]--[@b15-idr-12-359] PCR amplification for the individual *bla* gene was carried out in a Thermal Cycler (T100, Bio-Rad). A negative control (nuclease-free water) was included in each run. PCR products were electrophoresed on a 1% agarose gel containing ethidium bromide, and finally visualized in a gel documentation system (ChemiDoc XRS, Bio-Rad). Purified PCR products were sequenced (Sangon Biotech), and the sequencing results were forwarded for bioinformatics analysis using the Basic Local Alignment Search Tool online program (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

BF detection
------------

Crystal violet staining was performed in 96-well plates with all EC isolates sampled.[@b16-idr-12-359] For each EC isolate, a single colony was incubated in test tubes containing 5 mL of Luria--Bertani (LB) medium and then shake-cultured at 37°C for 18 hours. Then, 1 mL of bacterial suspension was trans-inoculated into a new test tube containing 5 mL of sterile LB medium. Each well of the sterile 96-well flat-bottomed plastic tissue culture plate with a lid was filled with 200 µL of bacterial suspension. Negative controls (blank) were LB broth alone, which was dispensed into eight wells per tray. After aerobic incubation at 37°C for 24 hours, the content of the wells was carefully drawn off and each well was washed three times with 250 µL of sterile physiological saline. Biofilms were stained with 0.2 mL of crystal violet (2%) for 5 minutes at room temperature. Unspecific staining in the wells was rinsed out three times with PBS. The plates were inverted on a towel, allowed to air dry, and the dye-stained adherent cells in each well were dissolved with 200 µL 30% acetic acids. The OD of re-solubilized crystal violet in each well was measured at a wavelength of 590 nm absorbance. All tests were carried out three times, with three wells per culture, and the results were averaged (cutoff value is 0.218; [Table S2](#SD3-idr-12-359){ref-type="supplementary-material"}).

Statistical analyses
--------------------

The mean and SD were calculated for continuous variables. Continuous variables with normal distribution were compared with the Student's *t*-test, and variables that were not normally distributed were compared with the Mann--Whitney *U* test. The chi-squared test was used to compare categorical variables. All statistically significant variables with *P*\<0.05 identified in the univariate analysis were further analyzed by multivariate logistic regression analysis. OR and 95% CI were calculated. Kaplan--Meier survival analysis was used to generate survival curves, and the difference between the survival curves was assessed by mean of the log-rank test. Cox regression analysis for the predictors of survival was performed. All significant variables related to mortality in the univariate analysis were entered into the multivariate model for further analysis. All analyses were performed using the SPSS version 23.0 software. Two-sided *P*-values \<0.05 were considered to have statistical significance.

Ethics approval and consent to participate
==========================================

The study was approved by the ethics committee of Tianjin Medical University Cancer Institute and Hospital. Waiving of informed consent was obtained due to the retrospective noninterventional study design. Data were collected anonymously.

Results
=======

Risk factors of ESBL-EC-caused BSI in cancer patients
-----------------------------------------------------

During the study period, 324 cases of EC-caused BSI in hospitalized cancer patients were identified, among which 160 episodes showed positive results and 164 episodes showed negative results in the ESBL confirmation test. In PCR detection of ESBL genotypes, 91.88% of the screened ESBL-positive EC isolates were found to possess one or more of the ESBL genes (*bla*~TEM~, *bla*~SHV~, and *bla*~CTX-M~) tested in this study ([Figure S1](#SD1-idr-12-359){ref-type="supplementary-material"}). The overall prevalence of ESBL genotypes in EC isolates is shown in [Figure 1](#f1-idr-12-359){ref-type="fig"}, and the main genotypes that predominated in these isolates were *bla*~CTX-M-15~ (31.29%) and *bla*~TEM-52~ plus *bla*~CTX-M-15~ (42.17%) ([Table S3](#SD4-idr-12-359){ref-type="supplementary-material"}).

The clinical characteristics of cancer patients with EC-caused BSI are summarized in [Table 1](#t1-idr-12-359){ref-type="table"}. EC-caused BSI occurred in 305 (94.14%) patients with solid tumors, among which most episodes were frequently acquired in patients with pancreatic cancer (61, 20.00%), hepatic carcinoma (49, 16.07%), followed by colorectal cancer (45, 14.75%), gastric carcinoma (43, 14.10%), and gynecological cancer (33, 10.82%). ESBL-EC-caused BSI was associated with recent exposure to antibiotics (cephalosporins and carbapenems), chemotherapy, and BF as determined by univariate analysis. Cancer patients with non-ESBL-EC-caused BSI had received more β-lactam/β-lactamase inhibitor combinations therapy compared to the ESBL-EC-caused BSI group. After applying a logistic regression model, independent risk factors for infection with ESBL-EC were therapy with third-generation cephalosporin (OR 0.30; 95% CI: 0.09--0.94; *P*=0.04), chemotherapy (OR 1.80; 95% CI: 1.12--2.89; *P*=0.02), and BF (OR: 2.79, 95% CI: 1.61--4.83; *P*\<0.001). BF-producing EC-caused BSI was significantly observed in colorectal cancers and hematological malignancies ([Table S4](#SD5-idr-12-359){ref-type="supplementary-material"}). To further determine the risk factors for BF, logistic regression analysis was again used in the regrouped data, and only the ESBL characteristic (OR 3.21; 95% CI: 1.86--5.53; *P*\<0.001) was shown as an independent risk factor for the BF phenotype ([Table 2](#t2-idr-12-359){ref-type="table"}).

Outcome difference among cancer patients with EC-caused BSI
-----------------------------------------------------------

The mortality rate was 21.91% (71/324) for all cancer patients with EC-caused BSI. The overall mortality was significantly higher in the BF-positive EC-caused BSI group compared to that in the BF-negative EC-caused BSI group (42.25% vs 20.16%; log-rank *P*\<0.001) ([Figure 2](#f2-idr-12-359){ref-type="fig"}). Compared with the BF-negative ESBL-EC-caused BSI group, the overall mortality was significantly higher in the BF-positive ESBL-EC-caused BSI group (*P*=0.001) ([Figure 3](#f3-idr-12-359){ref-type="fig"}).

Risk factor analysis between the survival and non-survival cancer patients is summarized in [Table 3](#t3-idr-12-359){ref-type="table"}. Univariate analysis results revealed that diabetes mellitus, LOS, ICU admission, metastasis, mechanical ventilation, BF, organ failure, and the presence of septic shock were significantly associated with death. After multivariate Cox regression analysis was performed, the variables that constituted independent predictors for mortality were metastasis (OR =2.71 95% CI: 1.59--4.63; *P*=0.001), ICU admission (OR =2.08, 95% CI: 1.13--3.84; *P*=0.02), BF (OR =2.20, 95% CI: 1.33--3.63; *P*=0.002), organ failure (OR =10.33, 95% CI: 5.92--18.03; *P*\<0.001), and the presence of septic shock (OR =2.17, 95% CI: 1.24--3.78; *P*=0.006).

Discussion
==========

In this study, we retrospectively collected the clinical microbiological characteristic of cancer patients with EC-caused BSI. We systematically evaluated the risk factors, survival difference, and mortality predictors for cancer patients with bloodstream-infected by EC with/without BF. The results showed that prior exposure to cephalosporins, chemotherapy, and BF were three independent risk factors for ESBL-EC-caused BSI. Cancer patients infected by BF-positive ESBL-EC had a lower survival rate. Metastasis, ICU admission, organ failure, septic shock, and BF-positive ESBL-EC infection were five independent risk factors for mortality. These data highlight that BF is closely associated with ESBL-EC-caused BSI and prominently affects the survival of BSI cancer patients.

EC is one of the most frequent causes of BSI in many tertiary care hospitals. Our previous studies revealed that cancer patients often suffer from treatment problems due to EC-caused BSI.[@b17-idr-12-359],[@b18-idr-12-359] In the present study, we further showed the high prevalence of MDR EC (49.38%) in cancer patients with BSI. PCR amplification based on gene-specific primers followed by nucleotide sequencing provides the easiest and most reliable method to detect the ESBL genotype.[@b15-idr-12-359],[@b19-idr-12-359],[@b20-idr-12-359] Previous studies reported a high prevalence of ESBL-EC in the Asia-Pacific area.[@b15-idr-12-359],[@b19-idr-12-359],[@b21-idr-12-359] Although the CTX-M type of ESBL is believed to be the dominant type in Europe and Asia,[@b15-idr-12-359],[@b19-idr-12-359],[@b22-idr-12-359],[@b23-idr-12-359] it was remarkable that in the present study, only 40.82% of ESBL-EC carried the *bla*~CTX-M~ genotype whereas 46.26% of ESBL-EC carried the *bla*~TEM~ plus *bla*~CTX-M~ genotype ([Figure 1](#f1-idr-12-359){ref-type="fig"}; [Table S3](#SD4-idr-12-359){ref-type="supplementary-material"}). This result was similar to several clinical observation conducted in other patients,[@b24-idr-12-359]--[@b27-idr-12-359] showing that TEMs genotype are frequently encountered in clinical isolates expressing the CTX-Ms genotype. The reason for co-occurrence of TEM and CTX-M genotypes in ESBL-EC is not clear. It may reflect the redistribution of resistant genes in immunocompromised cancer patients, or provide complementary contributions to the overall resistance of the ESBL producers.[@b28-idr-12-359] In addition, it was found that among the isolated ESBL-ECs, 49.38% carried two or three *bla* genes, which might also account for the high-level β-lactam-resistant phenotype.

BF is a unique mechanism exhibited by several microbes in order to survive in unfavorable conditions. It is a structured community of bacterial cells enclosed in a polymeric matrix and adherent to a surface.[@b9-idr-12-359] Biofilm-producing bacteria are highly resistant to antibiotic treatment. The ability of bacterial BF to adhere to medical devices and the use of invasive medical devices are widely recognized.[@b29-idr-12-359] It was reported that the prevalence of MDR in BF isolates are more common in comparison to non-BF isolates.[@b3-idr-12-359] We found that 81 (25.00%) EC isolates from 324 BSI cancer patients were biofilm producers. To our knowledge, this is the first report of BF in cancer patients with EC-caused BSI. Interestingly, it was found that BF was significantly higher in ESBL-positive EC isolates than in that of ESBL-negative isolates ([Table 1](#t1-idr-12-359){ref-type="table"}). This finding is similar to the investigations on other infectious types. The studies by Subramanian et al and Neupane et al reported similar observations in patients with urinary tract infections that ESBL-EC strains more frequently formed biofilm in comparison to that of non-ESBL-EC isolates.[@b30-idr-12-359],[@b31-idr-12-359] The reason of the higher ability of ESBL-EC strains to form biofilm is not clear. Activation of several stress response genes and expression of certain virulence genes during bacterial chromosomal gene rearrangements to acquire the ESBL plasmids may be the underlying mechanism.[@b30-idr-12-359]--[@b33-idr-12-359] Among these studies, enhanced biofilm formation capacity in ESBL-plasmid-carrying ST131 and ST648 strains that synthesize virulent- and survival-associated extracellular matrix components (eg, curli fimbriae and/or cellulose) was particularly notable. A deeper understanding of the contribution of transcription factor csgD to biofilm formation and motility capacity in pandemic ESBL-producing EC lineages may be the solution.[@b33-idr-12-359]

Although BF has been repeatedly described to increase the antibiotic resistance of microorganisms, one study showed it was not associated with any clinical characteristic in patients with EC bacteremia.[@b34-idr-12-359] Our study found that BF was not only significantly associated with ESBL-EC-caused BSI but was also an independent risk factor for mortality in BSI cancer patients ([Table 3](#t3-idr-12-359){ref-type="table"}). This finding highlights the equal importance of the BF contribution to mortality as the traditional factors, such as ICU admission, metastasis, organ failure, and shock. Our finding that BF was an independent predictor for mortality further confirms this point. These results are in line with a previous study on enterobacteriaceae-caused infections in non-cancer patients.[@b33-idr-12-359] The higher ability of the ESBL-EC to form biofilm increases the mortality and infection severity of cancer patients, making current treatments even more difficult. Therefore, adoption of alternative antibiotics (eg, rifampicin, gentamicin, azithromycin, clarithromycin, tigecycline, colistin, and daptomycin) that can disrupt or inhibit BF may be a good choice.[@b32-idr-12-359] Clinicians should take into account the use and doses of BF-response antibiotics to be on the safe side, as exposure to sub-inhibitory concentrations of these antibiotics can enhance BF. In addition, innovative approaches aimed at overcoming biofilm resistance to conventional antimicrobial agents should be tested in small-scale clinical trials. These include the use of weak organic acids (acetic acid used in hepatology/oncology and citric acid used in hematology/oncology/renal), photo irradiation (blue light therapy), and the application of bacteriophages (phage endolysin with anti-Gram-negative activity).[@b24-idr-12-359] Perhaps, combining aspects of these approaches can greatly benefit cancer patients with BF-positive ESBL-EC infection.

Limitations
-----------

This study was performed based on a heterogeneous cancer patients group in a single institution, which may present different clinical characteristics than other types of patients and may not reflect the epidemiology of other cancer centres in China. In addition, it is a pity that detailed typing of the ESBL genes was not done.

Conclusion
==========

This study showed that BF is not only significantly associated with the ESBL production by EC but is also an independent risk factor for mortality in hospitalized cancer patients with BSI. Our findings suggest that the combination of BF-positive ESBL-EC isolates with other appropriate laboratory indicators might benefit infection control and improve clinical outcomes, which may facilitate current antibiotic treatment and prognosis to BSI cancer patients.

Supplementary materials
=======================

###### 

Multiplex PCR analysis of ESBL-EC isolates.

**Notes:** PCR products from partial samples were separated in a 1% agarose gel. M, DNA ladder. P, positive control. Previously confirmed EC isolates containing *bla*~TEM~, *bla*~SHV~, and *bla*~CTX-M~ genes. N, negative control (ddH~2~O). Lanes 1--6 in (**A**--**C**), clinical EC isolates. The amplified product from each PCR is indicated on the right, and the size of the marker in base pairs is shown on the left.

**Abbreviation:** ESBL-EC, extended-spectrum β-lactamase-producing *Escherichia coli*.

###### 

PCR primers used for amplification of ESBL-related genes

  Target gene    Primer            Sequence (5′--3′)                                Amplicon size (bp)
  -------------- ----------------- ------------------------------------------------ --------------------
  *bla*~TEM~     Forward Reverse   AAAATTCTTGAAGACG TTACCAATGCTTAATCA               1,080
  *bla*~SHV~     Forward Reverse   GGGTTATTCTTATTTGTCGCT TAGCGTTGCCAGTGCTCG         929
  *bla*~CTX-M~   Forward Reverse   TTTGCGATGTGCAGTACCAGTAA CGATATCGTTGGTGGTGCCATA   544

**Abbreviation:** ESBL, extended-spectrum β-lactamase.

###### 

BF detection values by crystal violet staining

  Strains   OD~590~ value   Strains   OD~590~ value   Strains   OD~590~ value   Strains   OD~590~ value
  --------- --------------- --------- --------------- --------- --------------- --------- ---------------
                                                                                          
  1         0.352±0.025     82        0.258±0.107     163       0.175±0.028     244       0.613±0.059
  2         0.140±0.039     83        0.162±0.044     164       0.200±0.015     245       0.213±0.026
  3         0.412±0.092     84        0.099±0.014     165       0.142±0.057     246       0.140±0.052
  4         0.153±0.056     85        0.118±0.033     166       0.154±0.043     247       0.276±0.057
  5         0.135±0.066     86        0.220±0.088     167       0.124±0.028     248       0.172±0.038
  6         0.149±0.08      87        0.159±0.030     168       0.178±0.025     249       0.271±0.047
  7         0.211±0.096     88        0.100±0.019     169       0.155±0.048     250       0.175±0.026
  8         0.156±0.054     89        0.432±0.065     170       0.170±0.033     251       0.170±0.039
  9         0.401±0.067     90        0.137±0.078     171       0.139±0.052     252       0.179±0.025
  10        0.150±0.052     91        0.172±0.037     172       0.165±0.026     253       0.376±0.052
  11        0.275±0.05      92        0.129±0.052     173       0.188±0.029     254       0.120±0.033
  12        0.271±0.102     93        0.130±0.079     174       0.195±0.009     255       0.136±0.057
  13        0.234±0.049     94        0.168±0.039     175       0.275±0.053     256       0.166±0.049
  14        0.364±0.059     95        0.128±0.089     176       0.184±0.007     257       0.325±0.057
  15        0.148±0.064     96        0.172±0.038     177       0.166±0.031     258       0.127±0.051
  16        0.155±0.06      97        0.150±0.039     178       0.156±0.056     259       0.152±0.046
  17        0.146±0.039     98        0.137±0.056     179       0.154±0.024     260       0.184±0.031
  18        0.155±0.062     99        0.123±0.054     180       0.168±0.022     261       0.149±0.034
  19        0.128±0.039     100       0.156±0.061     181       0.586±0.038     262       0.354±0.047
  20        0.146±0.057     101       0.110±0.038     182       0.185±0.014     263       0.371±0.053
  21        0.154±0.058     102       0.144±0.054     183       0.141±0.021     264       0.137±0.051
  22        0.481±0.054     103       0.167±0.045     184       0.169±0.022     265       0.145±0.037
  23        0.565±0.073     104       0.322±0.051     185       0.197±0.014     266       0.164±0.028
  24        0.538±0.091     105       0.173±0.044     186       0.126±0.078     267       0.486±0.044
  25        0.152±0.037     106       0.286±0.091     187       0.179±0.038     268       0.581±0.062
  26        0.125±0.043     107       0.140±0.071     188       0.419±0.042     269       0.206±0.011
  27        0.145±0.042     108       0.128±0.059     189       0.152±0.049     270       0.185±0.012
  28        0.150±0.057     109       0.118±0.049     190       0.173±0.023     271       0.168±0.034
  29        0.340±0.048     110       0.169±0.046     191       0.154±0.057     272       0.118±0.033
  30        0.135±0.058     111       0.159±0.058     192       0.140±0.067     273       0.179±0.038
  31        0.158±0.045     112       0.262±0.099     193       0.195±0.013     274       0.191±0.015
  32        0.241±0.058     113       0.161±0.034     194       0.181±0.027     275       0.138±0.068
  33        0.270±0.068     114       0.149±0.067     195       0.169±0.044     276       0.294±0.042
  34        0.271±0.048     115       0.169±0.039     196       0.496±0.070     277       0.271±0.060
  35        0.142±0.064     116       0.152±0.057     197       0.252±0.114     278       0.179±0.037
  36        0.290±0.069     117       0.155±0.030     198       0.246±0.066     279       0.183±0.029
  37        0.152±0.05      118       0.331±0.043     199       0.137±0.03      280       0.189±0.014
  38        0.481±0.054     119       0.167±0.044     200       0.178±0.038     281       0.123±0.039
  39        0.158±0.037     120       0.139±0.051     201       0.341±0.055     282       0.330±0.060
  40        0.149±0.049     121       0.150±0.055     202       0.160±0.046     283       0.399±0.058
  41        0.231±0.040     122       0.162±0.051     203       0.139±0.059     284       0.111±0.017
  42        0.295±0.074     123       0.139±0.047     204       0.188±0.028     285       0.417±0.086
  43        0.335±0.074     124       0.490±0.050     205       0.171±0.029     286       0.275±0.077
  44        0.212±0.058     125       0.165±0.042     206       0.151±0.055     287       0.194±0.016
  45        0.133±0.064     126       0.138±0.070     207       0.184±0.027     288       0.163±0.054
  46        0.149±0.051     127       0.196±0.011     208       0.150±0.037     289       0.253±0.053
  47        0.422±0.107     128       0.628±0.064     209       0.140±0.074     290       0.129±0.047
  48        0.147±0.043     129       0.116±0.063     210       0.529±0.045     291       0.191±0.025
  49        0.305±0.079     130       0.173±0.044     211       0.169±0.038     292       0.156±0.052
  50        0.111±0.018     131       0.162±0.032     212       0.149±0.062     293       0.198±0.014
  51        0.157±0.047     132       0.581±0.075     213       0.144±0.055     294       0.816±0.043
  52        0.214±0.052     133       0.153±0.044     214       0.143±0.052     295       0.266±0.042
  53        0.364±0.060     134       0.189±0.019     215       0.132±0.082     296       0.090±0.013
  54        0.197±0.072     135       0.157±0.05      216       0.161±0.046     297       0.142±0.040
  55        0.145±0.064     136       0.187±0.015     217       0.189±0.025     298       0.130±0.029
  56        0.174±0.034     137       0.185±0.028     218       0.292±0.052     299       0.151±0.043
  57        0.237±0.088     138       0.182±0.013     219       0.369±0.045     300       0.146±0.040
  58        0.171±0.037     139       0.173±0.038     220       0.193±0.016     301       0.128±0.059
  59        0.282±0.087     140       0.206±0.007     221       0.139±0.055     302       0.103±0.023
  60        0.533±0.108     141       0.159±0.042     222       0.178±0.037     303       0.167±0.024
  61        0.129±0.012     142       0.196±0.017     223       0.183±0.027     304       0.198±0.017
  62        0.161±0.055     143       0.129±0.034     224       0.154±0.042     305       0.125±0.015
  63        0.260±0.080     144       0.167±0.041     225       0.171±0.037     306       0.179±0.037
  64        0.146±0.059     145       0.150±0.058     226       0.138±0.047     307       0.259±0.030
  65        0.475±0.059     146       0.396±0.027     227       0.117±0.042     308       0.183±0.032
  66        0.150±0.056     147       0.181±0.015     228       0.174±0.042     309       0.162±0.029
  67        0.371±0.099     148       0.174±0.022     229       0.167±0.026     310       0.325±0.049
  68        0.171±0.027     149       0.205±0.009     230       0.248±0.029     311       0.173±0.019
  69        0.134±0.072     150       0.115±0.052     231       0.156±0.037     312       0.138±0.064
  70        0.144±0.063     151       0.142±0.041     232       0.142±0.038     313       0.203±0.013
  71        0.150±0.048     152       0.150±0.039     233       0.184±0.027     314       0.134±0.048
  72        0.150±0.054     153       0.104±0.041     234       0.189±0.026     315       0.175±0.041
  73        0.127±0.034     154       0.073±0.022     235       0.123±0.061     316       0.169±0.044
  74        0.129±0.058     155       0.290±0.054     236       0.333±0.064     317       0.128±0.063
  75        0.156±0.054     156       0.225±0.065     237       0.110±0.024     318       0.151±0.048
  76        0.556±0.070     157       0.159±0.038     238       0.197±0.041     319       0.595±0.088
  77        0.157±0.052     158       0.173±0.039     239       0.166±0.038     320       0.170±0.035
  78        0.133±0.071     159       0.168±0.037     240       0.174±0.042     321       0.162±0.043
  79        0.155±0.046     160       0.147±0.045     241       0.140±0.060     322       0.200±0.017
  80        0.142±0.064     161       0.169±0.033     242       0.164±0.043     323       0.146±0.040
  81        0.124±0.063     162       0.162±0.036     243       0.180±0.004     324       0.132±0.033

**Abbreviation:** BF, biofilm formation.

###### 

Molecular characterization of *bla* genes in ESBL-EC isolates

  Genotype of the *bla* gene   No. of isolates
  ---------------------------- -----------------
                               
  TEM-52                       4
  SHV-11                       2
  SHV-12                       2
  CTX-M-1                      1
  CTX-M-14                     8
  CTX-M-15                     46
  CTX-M-28                     2
  CTX-M-19                     2
  CTX-M-27                     1
  TEM-3, SHV-12                2
  TEM-52, CTX-M-14             6
  TEM-52, CTX-M-15             62
  SHV-12, CTX-M-15             4
  SHV-12, TEM-52, CTX-M-15     5

**Abbreviation:** ESBL-EC, extended-spectrum β-lactamase-producing *Escherichia coli*.

###### 

Distribution of BF/non-BF EC-caused BSI in cancer patients

  Tumor type                                                        BF-EC (81)   non-BF-EC (243)   *P*-value
  ----------------------------------------------------------------- ------------ ----------------- -----------
                                                                                                   
  Hematological malignancies                                        9 (11.11)    10 (4.12)         0.020
  Lung cancer                                                       5 (6.17)     21 (8.64)         0.479
  Mammary cancer                                                    9 (11.1)     16 (6.58)         0.187
  Gynecological cancer[a](#tfn11-idr-12-359){ref-type="table-fn"}   6 (7.41)     27 (11.11)        0.341
  Colorectal cancer                                                 17 (20.99)   28 (11.52)        0.033
  Pancreatic cancer                                                 10 (12.35)   51(20.99)         0.085
  Hepatic carcinoma                                                 14 (17.28)   35 (14.40)        0.532
  Gastric carcinoma                                                 8 (9.88)     35 (14.40)        0.299
  Bladder cancer                                                    3 (3.70)     7 (2.88)          0.711
  Prostate cancer                                                   0            6 (2.47)          0.154
  Renal carcinoma                                                   0            2 (2.1)           0.413
  Others[b](#tfn12-idr-12-359){ref-type="table-fn"}                 0            5 (2.06)          0.194

**Notes:**

Includes cervical cancer, endometrial carcinoma, ovarian cancer.

Includes melanoma, buccal cancer, glioma, meningioma.

**Abbreviations:** BF, biofilm formation; BSI, bloodstream infection; EC, *Escherichia coli*.
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![Survival analysis of EC-caused BSI in cancer patients with/without BF.\
**Notes:** The Kaplan--Meier curve shows the survival curves until day 90 for the two infection groups. The mortality risk was higher among the cancer patients with BF-positive EC-caused BSIs compared with those with BF-negative EC-caused BSIs (*P*\<0.001).\
**Abbreviations:** BF, biofilm formation; BSI, bloodstream infection; EC, *Escherichia coli*; NBF BSI, BF-negative EC-caused bloodstream infections.](idr-12-359Fig2){#f2-idr-12-359}

![Survival analysis of ESBL-EC-caused BSI in cancer patients with/without BF.\
**Notes:** The Kaplan--Meier curve shows the survival curves until day 90 for the two infection groups. The mortality risk was higher among the cancer patients with BF-positive ESBL-EC-caused BSIs compared with those with BF-negative EC-caused BSIs (*P*=0.001).\
**Abbreviations:** BF, biofilm formation; EC, *Escherichia coli*; ESBL, extended-spectrum β-lactamase.](idr-12-359Fig3){#f3-idr-12-359}

###### 

Clinical characteristic of cancer patients with ESBL/non-ESBL EC-caused BSI

  Characteristics                                     ESBL (n=160), n (%)   Non-ESBL (n=164), n (%)   *P*-value   OR (95% CI)         *P*-value[a](#tfn1-idr-12-359){ref-type="table-fn"}
  --------------------------------------------------- --------------------- ------------------------- ----------- ------------------- -----------------------------------------------------
                                                                                                                                      
  Demographics                                                                                                                        
   Males, n (%)                                       74 (46.25)            82 (50.00)                0.50                            
   Age (years), median (range)                        61 (28--83)           62 (19--85)               0.26                            
  Comorbidities                                                                                                                       
   Hypertension                                       52 (32.50)            60 (36.59)                0.27                            
   Chronic heart disease                              23 (14.38)            29 (17.68)                0.34                            
   Diabetes mellitus                                  23 (14.38)            26 (15.85)                0.71                            
  Underlying disease                                                                                                                  
   Solid tumor                                        149 (93.13)           156 (95.12)               0.44                            
   Hematological disease                              11 (6.88)             8 (4.88)                                                  
  Source of BSI                                                                                                                       
   Abdominal infection                                35 (21.88)            41 (25.00)                0.43                            
   Urinary tract infection                            36 (22.50)            32 (19.51)                0.60                            
   Biliary infection                                  47 (29.38)            47 (28.66)                0.89                            
   Pulmonary infection                                26 (16.25)            30 (18.29)                0.73                            
   Catheter-related                                   8 (5.00)              3 (1.83)                  0.12                            
   Unknown origin                                     4 (2.50)              9 (5.49)                  0.26                            
   Others[b](#tfn2-idr-12-359){ref-type="table-fn"}   4 (2.50)              2 (1.22)                  0.39                            
  Previous exposure to antibiotics (within 1 month)                                                                                   
   Cephalosporin                                      34 (21.25)            20 (12.20)                0.03        0.30 (0.09--0.94)   0.04
   β-lactam/β-lactamase inhibitor                     17 (10.63)            36 (21.95)                0.01        0.98 (0.31--3.13)   0.98
   Carbapenem                                         95 (59.38)            79 (48.17)                0.04        0.43 (0.15--1.21)   0.11
   Combined                                           8 (5.00)              16 (9.76)                 0.06                            
   Aminoglycosides                                    6 (3.75)              13 (7.93)                 0.11                            
  LOS to the first positive culture                   30.89±24.65           29.18±19.27               0.49                            
  Invasive procedure                                  81 (50.63)            79 (48.17)                0.66                            
  Chemotherapy                                        106 (66.25)           84 (51.22)                0.01        1.80 (1.12--2.89)   0.02
  Surgery (within 1 month)                            79 (49.38)            94 (57.32)                0.15                            
  BF                                                  57 (35.63)            24 (14.63)                \<0.001     2.79 (1.61--4.83)   \<0.001

**Notes:**

Multivariate logistic regression analysis.

Intracranial infection; vagina infection; pelvic cavity infection.

**Abbreviations:** BF, biofilm formation; BSI, bloodstream infection; EC, *Escherichia coli*; ESBL, extended-spectrum β-lactamase; LOS, length of hospital stay (days).

###### 

Clinical characteristic of cancer patients with BF/non-BF EC-caused BSI

  Characteristics                                     BF-EC (n=81), n (%)   Non-BF-EC (n=243), n (%)   *P*-value   OR (95% CI)         *P*-value[a](#tfn4-idr-12-359){ref-type="table-fn"}
  --------------------------------------------------- --------------------- -------------------------- ----------- ------------------- -----------------------------------------------------
                                                                                                                                       
  Demographics                                                                                                                         
   Males, n (%)                                       31 (38.27)            125 (51.44)                0.04        0.59 (0.35--1.01)   0.05
   Age (years), median (range)                        61 (34--84)           63 (19--85)                0.38                            
  Comorbidities                                                                                                                        
   Hypertension                                       28 (34.57)            84 (34.57)                 1.00                            
   Chronic heart disease                              13 (16.05)            39 (16.05)                 1.00                            
   Diabetes mellitus                                  8 (9.88)              41 (16.87)                 0.13                            
  Underlying disease                                                                                                                   
   Solid tumor                                        74 (91.36)            231 (95.06)                0.22                            
   Hematological disease                              7 (8.64)              12 (4.94)                  0.22                            
  Source of BSI                                                                                        0.53                            
   Abdominal infection                                17 (20.99)            59 (24.28)                 0.50                            
   Urinary tract infection                            18 (22.22)            50 (20.58)                 0.81                            
   Biliary infection                                  23 (28.40)            71 (29.22)                 0.89                            
   Pulmonary infection                                19 (23.46)            37 (15.23)                 0.09                            
   Catheter-related                                   1 (1.23)              10 (4.12)                  0.22                            
   Unknown origin                                     3 (3.70)              10 (4.11)                  0.50                            
   Others                                             1 (1.23)              5 (2.05)                   0.64                            
  Previous exposure to antibiotics (within 1 month)                                                    0.85                            
   Third-generation cephalosporins                    16 (19.75)            38 (15.64)                 0.39                            
   β-lactam/β-lactamase inhibitor                     9 (11.11)             44 (18.11)                 0.14                            
   Carbapenems                                        48 (59.26)            126 (51.85)                0.25                            
   Combined                                           5 (6.17)              19 (7.82)                  0.62                            
   Aminoglycosides                                    3 (3.70)              16 (6.58)                  0.34                            
  Invasive procedure                                  39 (48.15)            121 (49.79)                0.80                            
  Surgery (within 1 month)                            44 (54.32)            129 (53.09)                0.90                            
  Chemotherapy                                        54 (66.67)            136 (55.97)                0.09                            
  ESBL                                                57 (70.37)            103 (42.39)                \<0.001     3.21 (1.86--5.53)   \<0.001

**Note:**

Multivariate logistic regression analysis.

**Abbreviations:** BF, biofilm formation; BSI, bloodstream infection; EC, *Escherichia coli*; ESBL, extended-spectrum β-lactamase.

###### 

Risk factors associated with the mortality of cancer patients with EC-caused BSI

  Characteristics                Survivors (n=253)   Non-survivors (n=71)   *P*-value   OR (95% CI)           *P*-value[a](#tfn6-idr-12-359){ref-type="table-fn"}
  ------------------------------ ------------------- ---------------------- ----------- --------------------- -----------------------------------------------------
                                                                                                              
  Demographics                                                                                                
   Age (years), median (range)   63 (19--85)         61 (34--80)            0.235                             
   Males (n %)                   128 (50.59)         28 (39.44)             0.112                             
  Comorbidities                                                                                               
   Hypertension                  92 (36.36)          20 (28.17)             0.192                             
   Chronic heart disease         42 (16.60)          10 (14.08)             0.558                             
   Diabetes mellitus             32 (12.65)          17 (23.94)             0.020       1.21 (0.67--2.17)     0.53
  Underlying disease                                                                                          
   Solid tumor                   240 (94.86)         65 (91.55)             0.231                             
   Hematological disease         13 (5.14)           6 (8.45)                                                 
  LOS                            29.05±21.69         34.70±23.45            0.048       1.00 (0.99--1.01)     0.96
  ICU admission                  19 (7.51)           15 (21.13)             0.002       2.08 (1.13--3.84)     0.02
  Invasive procedure             122 (48.22)         38 (53.52)             0.494                             
  Mechanical ventilation         56 (22.13)          42 (59.16)             \<0.001     1.27 (0.44--3.63)     0.66
  Metastasis                     100 (39.53)         46 (64.79)             \<0.001     2.71 (1.59--4.63)     0.001
  Chemotherapy                   147 (58.10)         43 (60.56)             0.712                             
  Surgery                        134 (52.96)         39 (54.93)             0.833                             
  Previous blood transfusion     98 (38.74)          31 (43.66)             0.520                             
  ESBL                           121 (47.83)         39 (54.93)             0.310                             
  BF                             51 (20.16)          30 (42.25)             \<0.001     2.20 (1.33--3.63)     0.002
  Organ failure                  12 (4.74)           47 (66.20)             \<0.001     10.33 (5.92--18.03)   \<0.001
  Sepsis shock                   17 (6.72)           29 (40.85)             \<0.001     2.17 (1.24--3.78)     0.006

**Note:**

Multivariate logistic regression analysis.

**Abbreviations:** BF, biofilm formation; BSI, bloodstream infection; EC, *Escherichia coli*; ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; LOS, length of hospital stay (days).
